I'm LongbridgeAI, I can summarize articles.Curanex Pharmaceuticals Inc reported a Q2 2026 net loss of $3.29M and diluted EPS of $(0.12), remaining pre-revenue. The company completed a GMP pilot batch for Phyto-N in February 2026 to support IND-enabling studies, targeting an IND submission for ulcerative colitis in Q4 2026. Higher operating costs from its August 2025 IPO contributed to the increased loss compared to the prior year.
Curanex Pharmaceuticals Inc reported a net loss of $(3.29M) for the second quarter ended June 30, 2026, with diluted loss per share of $(0.12). The company remains pre-revenue and reported no sales in the quarter, compared with a $(0.06M) net loss and effectively break-even EPS in the year-ago quarter.
Financial Highlights
- Revenue: No revenue reported for Q2 2026 or Q2 2025 (pre-revenue).
- Net income: $(3.29M) for Q2 2026, versus $(0.06M) in Q2 2025.
- Diluted EPS: $(0.12) for Q2 2026, versus $(0.00) in Q2 2025.
Business Highlights
- GMP manufacturing milestone: Completed a GMP pilot-scale batch of Phyto-N in February 2026 to support IND-enabling GLP studies.
- Preclinical & IND timeline: GLP toxicology, PK and safety studies are underway; the company is targeting an IND submission for ulcerative colitis in Q4 2026.
- R&D focus and pipeline expansion: Phyto-N is being prioritized for ulcerative colitis, with plans to expand into cancer cachexia and other inflammatory indications.
- Public company transition: Completed an IPO in August 2025, driving higher public-company operating costs and increased paid management compensation.
- Clinical pathway: If the IND is allowed, a Phase I trial is planned about 30 days later, with a potential Phase II and licensing options contingent on positive Phase I results.
Original SEC Filing: Curanex Pharmaceuticals Inc [ CURX ] - 10-Q - Aug. 14, 2026